Navigating the Frontiers of Metastatic Breast Cancer: A Letter from Dr. Kelly Shanahan

In the ongoing battle against metastatic breast cancer (MBC), the intersection of personal experience and clinical advocacy often serves as the most powerful catalyst for progress. Dr. Kelly Shanahan, a prominent voice within the patient advocacy community, recently provided a candid update on her own journey, while simultaneously outlining the strategic mission of METAvivor. Her message serves as both a sobering reminder of the volatility of MBC and a roadmap for patients navigating the increasingly complex landscape of precision oncology.

The Reality of Treatment Volatility: A Personal Update

For those living with metastatic breast cancer, time is not merely a measurement of days, but a resource to be managed alongside a shifting biological reality. Dr. Shanahan’s recent experience underscores the "busted" nature of life when clinical expectations collide with disease progression. While managing the recovery of a broken foot—courtesy of her eight-month-old puppy, Albus Dumbledore—Dr. Shanahan faced a more significant medical hurdle: the failure of her latest clinical trial drug.

Though the drug initially showed promise in stabilizing certain metastatic sites, the disease displayed its characteristic adaptability. Her cancer, originally highly ER/PR+ (estrogen/progesterone receptor positive), exhibited a biological shift, mutating to a low ER/PR- and HER2-low profile, with new progression identified in the liver.

The Clinical Pivot: Immunotherapy and Oral Chemotherapy

In consultation with her "village of oncologists," Dr. Shanahan has initiated a new treatment protocol involving immunotherapy, prompted by a high tumor mutational burden identified via liquid biopsy, paired with oral chemotherapy (capecitabine/Xeloda). Preliminary signs, such as the resolution of numbness in an area affected by a new metastasis, offer a sliver of cautious optimism. However, the true efficacy of this regimen remains pending, awaiting the definitive results of follow-up scans scheduled for the end of August.

Chronology of Advocacy and Innovation

The trajectory of METAvivor’s efforts in 2024 is defined by a commitment to education and proactive patient engagement. The following timeline outlines the upcoming milestones designed to bridge the gap between complex science and patient empowerment:

October 5: The "Stage IV Stampede and Summit" will feature a dedicated panel on biomarkers, providing critical education on how to navigate complex diagnostic results.
October 6: The Summit will be followed by a Hill Day, where advocates will bring the reality of MBC to the legislative forefront in Washington, D.C.
Late Fall 2024: A specialized webinar series will launch, focusing specifically on the clinical management of patients with multiple, overlapping biomarkers—a growing area of concern for those with treatment-resistant disease.
October 13: The annual "Light Up MBC" event, the organization’s flagship fundraiser, will take place, serving as a critical financial pillar for ongoing research grants.

Supporting Data: The Vital Importance of Biopsy

A core theme of Dr. Shanahan’s recent address is the imperative of clinical re-evaluation. When a patient experiences a "mixed response"—where some lesions shrink while others grow—the biological profile of the disease may have shifted.

The Role of Liquid Biopsies

Dr. Shanahan emphasizes that medical teams must prioritize biopsies of new metastatic sites whenever feasible. When tissue biopsies are not possible, liquid biopsies—blood tests that analyze circulating tumor DNA—are essential tools for identifying new mutations. These mutations often dictate the shift from hormone-based therapies to immunotherapy or targeted agents. By understanding the specific biomarkers at every stage of progression, patients and oncologists can make informed decisions that avoid "one-size-fits-all" treatments, which are rarely effective in the context of late-stage, mutating cancers.

Strategic Partnerships: Expanding the Reach

METAvivor is formalizing its commitment to patient education through a new strategic partnership with the Live from Stage 4 podcast. This collaboration aims to amplify the reach of expert knowledge by:

Direct Access to Experts: Featuring interviews with leading oncologists and researchers who are at the vanguard of MBC science.
Addressing Controversies: Facilitating panels that tackle the "gray areas" of treatment, including emerging research and the management of debilitating side effects.
Highlighting Patient Initiatives: Showcasing METAvivor’s R.I.S.E (Reach. Inform. Support. Empower) program, which provides structured peer-to-peer support for those navigating the psychological and physical burdens of the disease.

By leveraging audio-first platforms, METAvivor is ensuring that critical information reaches patients who may be too physically fatigued by treatment to engage with traditional text-heavy resources.

The Implications for Research and Funding

At the heart of the METAvivor mission is the peer-reviewed grant process. Dr. Shanahan confirmed that the current cohort of patient advocate reviewers is moving into the evaluation phase of the year’s grant applications.

Why Patient Reviewers Matter

The involvement of patients in the grant-review process is a cornerstone of the organization’s methodology. While PhDs and MDs evaluate the scientific viability of a study, patient advocates evaluate its relevance to quality of life, the manageability of side effects, and the potential for immediate clinical impact. This dual-layer review process ensures that every dollar funded by the organization is directed toward research that truly moves the needle for the metastatic community.

For those interested in participating in the future of research funding, METAvivor maintains an open inquiry system for those wishing to serve as reviewers for the next cycle.

Conclusion: A Call to Action

The message from Dr. Shanahan is a testament to the resilience required of the MBC community. "METAvivor exists for and because of you," she notes, underscoring that the organization’s strength is derived entirely from the participation of those it serves.

Whether through fundraising, volunteerism, or the sharing of innovative ideas, the community is invited to take an active role in the organization’s evolution. As the fall season approaches, the focus remains clear: to continue pushing the boundaries of what is possible in MBC care, to advocate for research that addresses the mutations and adaptations of the disease, and to ensure that no patient faces their diagnosis in a vacuum of information.

As the community prepares for the upcoming Light Up MBC event, the goal remains the same as it has been since the organization’s inception: to provide the resources, the science, and the community support necessary to turn metastatic breast cancer from a terminal diagnosis into a manageable, chronic condition—and eventually, to find a cure.